Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Mylan
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
0.0%
0.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:VulnerableThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Teva Pharmaceuticals
Competitor Displacement Rate
0.0%
Competitors are displacing Mylan in 0.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Mylan, now part of Viatris, faces competition in the generic pharmaceutical market. Its displacement is due to larger market share and established distribution of competitors.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[goodrx.com][drugs.com]⚠️ Identified Vulnerability:Market Share
Primary Threat Identified:Teva Pharmaceuticals
Target Persona:Pharmacists and Patients
🚨 Threat Velocity:3/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)